The Week in Review: April 14, 2017 – April 21, 2017

Friday, April 21, 2017 News Recap Canada Well the last report from the final leg of HepCBC’s Road Trip to BC’s Interior 2017 is in. What a journey!! – and so much work!! This report focusses on events in the Kootenay region of BC, and I’m really impressed at how much Rosemary and Cheryl were able to accomplish!  Amazing. Awareness of hepatitis C in BC’s more remote and small communities is growing and this is due to the hard work of the many advocat...

Hepatitis C Patients at No Elevated Risk of Developing HCC Following DAA Compared to Interferon

Patients were at no elevated risk of developing hepatocellular carcinoma (HCC) after achieving sustained virologic response (SVR) following treatment with direct-acting antiviral therapy (DAA) for hepatitis C compared to interferon therapy, according to results of a meta-analysis reported at the 2017 International Liver Congress (ILC). The data reflected that there was no difference in liver cancer risk following cure with either therapy. However, achievi

The Week in Review: Feb 3, 2017 – Feb 10, 2017

Friday, February 10, 2017 News Recap Liver Cancer In the news this week was a story about why Toronto, Canada, is a liver cancer hotspot. More than a thousand deaths from liver cancer every year in Ontario — and most of these occur in the Greater Toronto Area. The reasons: Hepatitis B & C in the immigrant populations, and the lack of screening of Baby Boomers in Canada.  This is terrible, especially considering that the survival rate from liver ...

The impact of sustained virological response to HCV infection on long term risk of hepatocellular carcinoma: the BC Hepatitis Testers Cohort

A study of the entire population of people treated for hepatitis C in British Columbia province between 1990 and 2013, Canada found that the risk of liver cancer was reduced by 80% in people cured of hepatitis C compared to those who were not cured. This study did not look at the relationship between exposure to DAAs and liver cancer risk. The study identified 8147 people treated with interferon-based regimens, 57% of whom were cured. Treated individuals

Direct-Acting Antiviral Treatment Linked with HCC Recurrence for Patients with Hepatitis C Infection

Data from 2 recent studies indicate that patients infected with hepatitis C virus (HCV) who were treated with direct-acting antiviral (DAA) therapy were more likely to experience a recurrence of hepatocellular carcinoma (HCC) than those who had no previous history of the disease. Results from a retrospective cohort study indicate that HCC recurrence occurred at a rate of 29% in patients with cirrhosis who had a history of previous HCC compared with 3.2%...

High rate of cancer recurrence found in certain hepatitis C patients

Scientists call for close monitoring of hepatitis C virus patients prescribed direct-acting antivirals, particularly for those with a history of liver cancer European Association for the Study of the Liver April 13, 2016, Barcelona, Spain: Data from a new study show that patients with Hepatitis C virus (HCV) taking direct-acting antiviral treatments (DAAs), who have previously fought off hepatocellular carcinoma (HCC), the most common form of liver